UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net (loss) income including noncontrolling interests in subsidiaries	$ (189)	$ 9,447
Adjustments to reconcile net (loss) income including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:
Depreciation, depletion and amortization	4,568	3,381
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	0	(5,023)
Change in fair value of Series B warrants	0	(11,628)
Compensation expense for share-based awards	858	477
Loss (gain) on foreign currency exchange	18	(80)
Change in fair value of equity securities	26,701	(3,343)
(Gain) loss on sale of equity securities	(28,861)	1,361
Unrealized loss on derivatives	629	0
Deferred income taxes	(3,652)	(240)
Changes in assets and liabilities:
Accounts receivable	65,156	(451)
Inventories	1,041	(503)
Prepaid expenses and other assets	(10,752)	(391)
Accounts payable and accrued expenses	7,108	2,355
Royalties and contingent legal fees payable	(7,811)	360
Deferred revenue	25	(71)
Net cash provided by (used in) operating activities	54,839	(4,349)
Cash flows from investing activities:
Purchases of equity securities	(15,544)	(5,166)
Sales of equity securities	57,854	8,032
Net purchases of property and equipment and additions to oil and gas properties	(270)	(83)
Net cash provided by investing activities	42,040	2,783
Cash flows from financing activities:
Borrowings on the Revolving Credit Facility	2,500	0
Dividend on Series A Redeemable Convertible Preferred Stock	0	(700)
Taxes paid related to net share settlement of share-based awards	(674)	(416)
Net cash provided by financing activities	1,826	77,995
Effect of exchange rates on cash and cash equivalents	(34)	12
Increase in cash and cash equivalents	98,671	76,441
Cash and cash equivalents, beginning	340,091	287,786
Cash and cash equivalents, ending	438,762	364,227
Supplemental schedule of cash flow information:
Interest paid	319	0
Income taxes paid	116	147
Noncash investing and financing activities:
Accrued patent costs	(4,000)	6,000
Rights Offering
Cash flows from financing activities:
Proceeds from Warrant Exercises	$ 0	$ 79,111